Elevated Lp(a) is unusual among cardiovascular markers: you can't meaningfully lower it with lifestyle. That makes the interpretation — and the strategic response — different from almost every other biomarker on this site.
Lp(a) above 125 nmol/L (≈50 mg/dL) means you carry a genetically elevated concentration of an atherogenic particle that is structurally more dangerous than ordinary LDL. Lp(a) particles are adhesive to arterial walls, prone to triggering platelet aggregation and thrombosis, and resistant to degradation by the endothelium.[1]
The key context: this risk is additive to your other cardiovascular risk factors, not a replacement for them. Someone with elevated Lp(a) and otherwise excellent metabolic health — normal ApoB, low fasting insulin, no hypertension, non-smoker — has a meaningfully different absolute risk profile than someone with elevated Lp(a) plus insulin resistance and an ApoB of 110 mg/dL.
The 2026 ACC/AHA guideline designates elevated Lp(a) as a risk-enhancing factor — meaning it shifts the threshold for treatment of other risk factors downward. If your LDL-C target was 100 mg/dL, elevated Lp(a) moves it toward 70 mg/dL. It's an amplifier of overall risk, not an isolated disease.
Because Lp(a) itself is not directly modifiable by lifestyle, the response is to maximize control of every factor that is modifiable. Think of elevated Lp(a) as raising the stakes on the other levers you can pull.
Elevated Lp(a) without knowing ApoB, LDL-C, hs-CRP, fasting insulin, and blood pressure leaves you interpreting one piece of a multi-factor picture. Order the complete set.
Quest Health — order full cardiovascular panel →
With elevated Lp(a), the standard ApoB target of under 80 mg/dL becomes more important, not less. Some clinicians argue for targeting below 70 mg/dL in the presence of Lp(a) elevation. ApoB responds to lifestyle: reduce refined carbohydrates, increase omega-3s, increase zone 2 aerobic activity.
ApoB guide — targets and how to lower it →
Insulin resistance and elevated Lp(a) together create a compounded cardiovascular risk that is greater than either alone. High fasting insulin (above 7 µIU/mL) in the presence of elevated Lp(a) is a combination that warrants serious lifestyle intervention and possibly clinical management.
Interpret high fasting insulin →
Lp(a) promotes arterial inflammation. hs-CRP reflects the inflammatory state of the arterial wall. With elevated Lp(a), low-grade inflammation is a more important target than it would be in a low-Lp(a) individual. The combination of high Lp(a) and high hs-CRP is particularly dangerous.
hs-CRP guide →
While omega-3s don't directly lower Lp(a), EPA+DHA reduce triglycerides, lower hs-CRP, and provide independent cardiovascular benefit. In the context of elevated Lp(a), the case for consistent high-dose omega-3 supplementation (2–4g EPA+DHA daily) is stronger than it would be otherwise.[2] Test your omega-3 index to confirm adequate status rather than assuming supplementation is sufficient.
Hypertension combined with elevated Lp(a) is a particularly dangerous pairing because Lp(a)'s thrombogenic effects are amplified by endothelial stress from high blood pressure. Target below 120/80 mmHg. If you haven't measured, do it this week.
Lp(a) is inherited in an autosomal dominant pattern. Each of your parents, siblings, and children has approximately a 50% chance of also having elevated Lp(a). The 2026 ACC/AHA guideline explicitly recommends cascade testing. Sharing your result and recommending they get tested is one of the most impactful things you can do.
The most significant development in Lp(a) science is not dietary — it's pharmaceutical. Two RNA-interference therapies in advanced clinical trials reduce Lp(a) by 80–95%:
If your Lp(a) is very high (above 300 nmol/L) and you are managing significant cardiovascular risk, ask your physician about clinical trial eligibility or access to PCSK9 inhibitors for the combined LDL-C and partial Lp(a) benefit.
Elevated Lp(a) is best thought of as a permanently raised baseline cardiovascular risk from one genetic source. You cannot remove it. What you can do is:
The goal is not zero cardiovascular risk — that doesn't exist. The goal is making every modifiable factor as favorable as possible given the genetic hand you were dealt.
Your most important modifiable cardiovascular target. With elevated Lp(a), getting ApoB below 80 mg/dL is more important than ever.
Arterial inflammation amplifies Lp(a)'s effects. Target below 0.5 mg/L.
Insulin resistance + elevated Lp(a) = compounded risk. Resolve insulin resistance first.
Glucose dysregulation worsens cardiovascular outcomes in people with elevated Lp(a). Target below 5.3%.
A high Lp(a) result should push you beyond generic cholesterol advice. SelfDecode gives you a way to connect inherited risk, cardiovascular reports, and lab data so your next steps are more personalized.
Explore SelfDecodeFor cardiometabolic risk, the highest-value home measurements are blood pressure, glucose response, and rhythm awareness.
Supplements should come after the baseline: labs, sleep, training, nutrition, and symptoms. For the supplements CreusLife recommends most often, Momentous is now the preferred partner because it offers focused products for performance, sleep, recovery, and longevity.
Start with the Momentous main store if you want to choose from the full lineup.
Lp(a) is one piece. ApoB, hs-CRP, fasting insulin, and HbA1c complete the picture. Order the full panel through Quest Health — no doctor required.